ClinicalTrials.gg
CompletedNCT06637072Updated Apr 6, 2026

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

A Phase 4 interventional study of Efgartigimod PH20 SC in Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by argenx. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by argenx · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Enrollment
34th of 42
23 · median 74
Started
2024
with 2 others
Phase 4
2 of 55
1 open now
Registered
39th of 55
by date
Lead sponsor
7 of 55
argenx

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 34th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 4, and was the 39th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and the local legal age of consent
  • Is diagnosed with CIDP (confirmed or possible CIDP) according to the criteria of the European Academy of Neurology/Peripheral Nerve Society
  • Is being treated with IVIg every 3-6 weeks, on a stable dose and dosing interval (between 0.5-2 g/kg) for at least 3 doses
  • If receiving oral , this should be at a stable dose of less than 20 mg a day or less than 40 mg every other day, for at least a month.
  • If receiving nonsteroidal medication, this should be at a stable dose for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Besides the indication under study, known disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk
  • Types of other polyneuropathy other than CIDP
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Efgartigimod PH20 SC

    Participants start efgartigimod PH20 SC treatment after discontinuing IVIg

    Biological: Efgartigimod PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants who begin treatment with efgartigimod PH20 SC within 1 week after stopping IVIg therapy and are still receiving efgartigimod PH20 SC at the end of the 12-week treatment period

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Changes from baseline in EQ-5D-5L scores over time

    Time frame: Up to 12 weeks

  2. Changes from baseline in TSQM-9 scores over time

    Time frame: Up to 12 weeks

  3. Changes from baseline in PGI-C scores over time

    Time frame: Up to 12 weeks

  4. Changes from baseline in PGI-S scores over time

    Time frame: Up to 12 weeks

  5. Incidence of (S)AEs

    Time frame: Up to 16 weeks

07

Study locations

13 sites
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • Neurology Associates PA
    Maitland, Florida 32751, United States
  • Visionary Investigators Network
    Miami, Florida 33180, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Velocity Clinical Research
    Lafayette, Louisiana 70508, United States
  • SRI International - ClinEdge
    Plymouth, Michigan 48170, United States
  • Velocity Clinical Research
    Raleigh, North Carolina 27607, United States
  • Erlanger Neuroscience Institute
    Chattanooga, Tennessee 37403, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • National Neuromuscular Research Institute
    Austin, Texas 78759, United States
  • Horizon Clinical Research: Gill Neuroscience
    Cypress, Texas 21216, United States
  • Northwest Houston Neurology - Cypress
    Cypress, Texas 77429, United States
  • Cedar Health Research - Dallas
    Dallas, Texas 75251, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Feb 2026, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 15, 2024
StartActual
Dec 10, 2024
Primary completionActual
Feb 19, 2026
CompletionActual
Feb 19, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06637072
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Dec 10, 2024
Primary completion
Feb 19, 2026
Completion
Feb 19, 2026
Last update
Apr 6, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion